A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs RG 6061 (Primary)
  • Indications Liver cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 13 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2017 Planned End Date changed from 17 Nov 2017 to 31 Jan 2018.
    • 14 Dec 2017 Planned primary completion date changed from 17 Nov 2017 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top